Alumis, Envudeucitinib, ONWARD1, ONWARD2, ONWARD3, Phase 3 Clinical Trial, Plaque Psoriasis, Psoriasis Treatment, TYK2 Inhibitor, Dermatology, Scalp Psoriasis,

SOUTH SAN FRANCISCO, Calif. — October 9, 2026 Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing targeted therapies...